A 60-year-old postmenopausal female patient with a previous history of Colle’s fracture came with complaints of lower backache. On evaluation, her T score was -2.5. Which of the following statements are false about the management of her condition?

Correct Answer: D. Bisphosphonates are not given for more than a year

This patient has osteoporosis (T score ≤ −2.5) with a fragility fracture history, meeting diagnostic criteria per Indian guidelines. The statement "Bisphosphonates are not given for more than a year" is FALSE because bisphosphonates are the first-line agents for osteoporosis management and are typically continued for 3–5 years minimum, often longer depending on fracture risk reassessment. Current evidence (NAMS, IOF, and Indian Osteoporosis Society guidelines) supports prolonged bisphosphonate therapy to reduce vertebral and non-vertebral fracture risk. Extended therapy (beyond 5 years) may be considered in high-risk patients. The misconception that bisphosphonates should be stopped after 1 year stems from outdated concerns about osteonecrosis of the jaw (ONJ) and atypical fractures, but these risks are rare and do not justify premature discontinuation in typical osteoporosis patients. Stopping bisphosphonates after only 1 year leaves the patient vulnerable to rapid bone loss and fracture recurrence, particularly in a postmenopausal woman with established osteoporosis and prior Colle's fracture.

Why the other options are wrong

A. Calcium requirements is 1200 mg per day — This statement is TRUE and reflects Indian and international guidelines. Postmenopausal women with osteoporosis require 1000–1200 mg elemental calcium daily (as per NAMS, IOF, and Indian Osteoporosis Society). This is a standard, evidence-based recommendation and is NOT false. Calcium supplementation is foundational in osteoporosis management. B. Oral vitamin D3 is given along with oral calcium — This statement is TRUE. Vitamin D3 (cholecalciferol) 800–2000 IU daily is routinely co-prescribed with calcium to enhance intestinal calcium absorption and improve bone health outcomes. This is standard practice in Indian clinical settings and aligns with all major guidelines. Vitamin D deficiency is endemic in India and must be corrected. C. Teriparatide should be started before supplementing with bisphosphonates — This statement is TRUE. Teriparatide (recombinant PTH 1–34) is an anabolic agent reserved for severe osteoporosis or bisphosphonate failure. When used, it is initiated BEFORE bisphosphonates because bisphosphonates blunt teriparatide's anabolic effect. However, teriparatide is expensive and not first-line in India; bisphosphonates remain the DOC. This is a correct sequencing principle, not false.

High-Yield Facts

Mnemonics

BONECARE (Bisphosphonate Duration) Bisphosphonates = 3–5 years minimum (not 1 year) | Osteoporosis = T ≤ −2.5 | Need Calcium 1200 mg + D (Vitamin D) | Early Anabolics (Teriparatide) Require Early use (before bisphosphonates). Use when reviewing osteoporosis DOC and duration. CAST (Calcium + Vitamin D + Bisphosphonates + Time) Calcium 1200 mg | Always add Vitamin D | Start Bisphosphonates (first-line) | Treat for 3–5+ years (not 1 year). Quick recall for osteoporosis management pillars.

NBE Trap

NBE exploits the outdated fear of bisphosphonate-related adverse events (ONJ, atypical fractures) to lure students into believing short-term therapy (1 year) is safer. In reality, premature discontinuation increases fracture risk far more than rare adverse events. The trap conflates "caution with bisphosphonates" with "stop after 1 year."

Clinical Pearl

In Indian clinical practice, postmenopausal women with osteoporosis and prior fragility fractures (like Colle's) are at high risk for hip and vertebral fractures. Continuing bisphosphonates for 3–5 years significantly reduces this risk; stopping after 1 year is a common prescribing error that leads to recurrent fractures and disability in elderly Indian women.

_Reference: KD Tripathi Pharmacology (Ch. Endocrine Pharmacology – Bisphosphonates); Harrison's Principles of Internal Medicine (Ch. 397 – Osteoporosis); Robbins & Cotran Pathologic Basis of Disease (Ch. 26 – Bone Pathology)_